The hype field of the Microbiome could be taking a step back, as the most advanced program has failed to meet its primary endpoint in a Phase II trial. What does this mean for the emerging class of therapies?
As we have seen at Refresh’s Microbiome fireside chat, the field took really big steps in its recent history. In a few years, it went from an exploding area of research (highlighting surprising connections) to the creation of Biotechs focusing on the development of Microbiome-based therapies.
The expectations for the field are high – it could yield breakthroughs for many diseases, from autoimmune diseases to cancer.
Seres Therapeutics raised an impressive $134M in its IPO (on top of massive deals like the €1.7Bn collaboration with Nestlé). It also had the most advanced therapy in the field, consisting of bacterial spores (SER-109) for the treatment of recurrent Clostridium difficile infections.
Now, the results of SER-109 Phase II trials (Ecospor) are giving a hard time to the company and the Microbiome field.